136024-60-7

Basic information

• Product Name: (2S,4R)-1-BOC-4-BENZYLOXY-PYRROLIDINE-2-DICARBOXYLIC ACID METHYL ESTER
• Synonyms: (2S,4R)-1-BOC-4-BENZYLOXY-PYRROLIDINE-2-DICARBOXYLIC ACID METHYL ESTER
• CAS NO: 136024-60-7
• Molecular Formula: C₁₈H₂₅NO₅
• Molecular Weight: 335.39
• Mol File: 136024-60-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S,4R)-1-BOC-4-BENZYLOXY-PYRROLIDINE-2-DICARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-1-BOC-4-BENZYLOXY-PYRROLIDINE-2-DICARBOXYLIC ACID METHYL ESTER(136024-60-7)
• EPA Substance Registry System: (2S,4R)-1-BOC-4-BENZYLOXY-PYRROLIDINE-2-DICARBOXYLIC ACID METHYL ESTER(136024-60-7)

Safety Data

• Hazardous Substances Data: 136024-60-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2S,4R)-1-BOC-4-BENZYLOXY-PYRROLIDINE-2-DICARBOXYLIC ACID METHYL ESTER is used as a chiral building block for the synthesis of pharmaceuticals and bioactive molecules. Its stereochemical properties and versatility make it a valuable component in the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2S,4R)-1-BOC-4-BENZYLOXY-PYRROLIDINE-2-DICARBOXYLIC ACID METHYL ESTER is utilized as a key intermediate for the preparation of various compounds with potential medicinal applications. Its unique structure allows for the creation of novel molecules with specific biological activities.
Used in Drug Development:
(2S,4R)-1-BOC-4-BENZYLOXY-PYRROLIDINE-2-DICARBOXYLIC ACID METHYL ESTER plays a crucial role in drug development, where it is employed as a precursor in the synthesis of new drug candidates. Its ability to be modified and incorporated into complex molecular structures makes it an essential tool for researchers in the pharmaceutical industry.

Upstream product

• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 51-35-4 4R-4-hydroxyproline 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 100-39-0 benzyl bromide 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 

Downstream Products

• 66831-17-2 (2S,4R)-methyl 4-(benzyloxy)pyrrolidine-2-carboxylate hydrochloride 
• 1640024-27-6 C₂₂H₃₁N₃O₆ 
• 1620320-28-6 (7R,8aS)-3-allyl-7-(benzyloxy)hexahydropyrrolo[1,2-d][1,2,4]triazine-1,4-dione 
• 1620320-33-3 (7R)-7-(benzyloxy)-3-(but-3-en-1-yl)hexahydropyrrolo[1,2-d][1,2,4]triazine-1,4-dione 
• 1640032-52-5 C₂₃H₃₃N₃O₆ 
• 1446652-29-4 (2S,4R)-4-(benzyloxy)-1-(2,2-diphenylacetyl)pyrrolidine-2-carboxylic acid 
• 1446653-92-4 C₂₇H₂₇NO₄ 
• 113490-76-9 4(R)-(phenylmethoxy)-(S)-proline methyl ester 
• 1403945-53-8 (2S,4R)-tert-butyl 4-(benzyloxy)-2-(5-bromo-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydropyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidine-1-carboxylate 
• 1403945-55-0 (2S,4R)-tert-butyl 4-(benzyloxy)-2-(3-bromo-2-(3,5-difluorophenylcarbamoyl)-1H-pyrrol-1-ylcarbamoyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES

Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

N-methyl-D-aspartate receptor modulators and methods of making and using same

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

cis-4-Alkoxydialkyl- and cis-4-Alkoxydiarylprolinol Organocatalysts: High Throughput Experimentation (HTE)-Based and Design of Experiments (DoE)-Guided Development of a Highly Enantioselective aza-Michael Addition of Cyclic Imides to α,β-Unsaturated Aldehydes

A diverse family (37 compounds) of cis-4-alkoxydiorganylprolinol derivatives has been prepared and evaluated in organocatalysis for the first time. The combined use of high throughput experimentation (HTE) techniques with efficient analytical methods has led to the identification of two superior catalysts for the enantioselective addition of succinimide to α,β-unsaturated aldehydes. Further optimization of the reaction conditions with design of experiments (DoE) techniques established the catalyst of choice for the considered aza-Michael reaction, the corresponding adducts (12 examples) being obtained in good yields and excellent enantioselectivities (succinimide and maleimide donors). The synthetic versatility of these Michael adducts is illustrated by a two-step sequence leading to enantiopure 1,3-amino alcohols. (Figure presented.).

Diastereoselective synthesis of novel aza-diketopiperazines via a domino cyclohydrocarbonylation/addition process

Herein, we report an unprecedented, short and diastereo-selective synthesis of newly reported aza-diketopiperazine (aza-DKP) scaffolds starting from amino acids. The strategy is based on a Rh(i)-catalyzed hydroformylative cyclohydrocarbonylation of allyl-substituted aza-DKP, followed by a diastereoselective functionalization of the platform. This methodology allows the synthesis of novel bicyclic and tricyclic aza-DKP scaffolds incorporating six- or seven-membered rings, with potential applications in medicinal chemistry. This journal is the Partner Organisations 2014.

L-Proline derived nitrogenous steroidal systems: An asymmetric approach to 14-azasteroids

An efficient chiral pool approach using l-proline to access 14-azasteroids under mild reaction conditions has been described. The key step involves the intramolecular SN2′ cyclization reaction for the construction of critical C-ring in the nitrogen impregnated steroidal architectures bearing unsaturation at Δ9(11) position. In the endeavour to synthesize some new congeners, the remote electronic impact of the electron donating groups in A ring and heteroatoms like oxygen in B ring, on the propensity of C-ring cyclization was also observed.

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS

New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

Synthesis of a constrained tricyclic scaffold based on trans-4-hydroxy-L- proline

Drug discovery research has taken advantage of peptidomimetic chemistry in order to achieve new leads possessing structural and functional characteristics of bioactive peptides together with enhanced metabolic resistance towards proteases. Herein is repor

New methods and reagents in organic synthesis. 92. A stereoselective synthesis of tilivalline and its analogs

Tilivalline (1a), a metabolite from Klebsiella pneumoniae var. oxytoca, and its derivatives 1 have been efficiently and stereoselectively synthesized from diphenyl phosphorazidate, the 2-oxazoline 2, the L-proline derivatives 5, and indole; the key step is a Mannich type intramolecular cyclization accompanied with completely stereoselective introduction of indole. Furthermore, 11-substituted 5H- pyrrolo[2,1-c][1,4]benzodiazepin-5-ones (16) have been also synthesized from the acetal amide 9a and various nucleophiles by the use of this new Mannich type cyclization.